Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 28.75 GBp
Change Today +0.50 / 1.77%
Volume 173.7K
As of 11:35 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

scancell holdings plc (SCLP) Snapshot

28.25 GBp
Previous Close
28.25 GBp
Day High
29.00 GBp
Day Low
28.25 GBp
52 Week High
10/30/14 - 40.00 GBp
52 Week Low
03/31/15 - 22.75 GBp
Market Cap
Average Volume 10 Days
-0.01 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for SCANCELL HOLDINGS PLC (SCLP)

Related News

No related news articles were found.

scancell holdings plc (SCLP) Related Businessweek News

No Related Businessweek News Found

scancell holdings plc (SCLP) Details

Scancell Holdings PLC, a biopharmaceutical company, engages in the discovery and development of novel immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms in the United Kingdom. It is involved in the development of SCIB1, a plasmid DNA vaccine, which is in I/II clinical trials for the treatment of melanoma; and SCIB2 that stimulates immune responses to the lung cancer antigen NY-ESO-1. The company has collaborations with Cancer Research Technology Limited; Immatics Biotechnologies GmbH; NIH; ImmunoVaccine Technologies; Ichor Medical Systems; and Merck KGaA. Scancell Holdings PLC was incorporated in 2008 and is based in Nottingham, the United Kingdom.

7 Employees
Last Reported Date: 09/3/14
Founded in 2008

scancell holdings plc (SCLP) Top Compensated Officers

Joint Chief Executive Officer, Chief Scientif...
Total Annual Compensation: 76.7K GBP
Joint Chief Executive Officer and Director
Total Annual Compensation: 70.0K GBP
Compensation as of Fiscal Year 2014.

scancell holdings plc (SCLP) Key Developments

Scancell Holdings plc Announces SCIB2 Synergy with Checkpoint Inhibitor Blockade for Treatment of Lung, Oesophageal, Prostate and Other Epithelial Cancers

Scancell Holdings plc announced new data demonstrating that animals treated with a combination of SCIB2, the company’s ImmunoBody vaccine in development for the treatment of lung, oesophageal, prostate and other epithelial cancers, and checkpoint inhibition (blockade of the CTLA-4 immune checkpoint pathway), showed enhanced tumour destruction and significantly longer survival times than when either treatment was used alone. The data confirming the therapeutic effect of SCIB2 with this second checkpoint pathway follows previous announcement on 12 August 2014 of SCIB1's synergy with PD-1 blockade in animal models. In earlier pre-clinical studies, they have shown that administration of SCIB2 alone induced potent tumour-specific T cell responses associated with increased T cell infiltration into the tumour and enhanced proliferation of T cells within the tumour resulting in tumour rejection and long term survival. In the new study where higher doses of tumour cells were used, the combination of CTLA-4 blockade with SCIB2 vaccination resulted in a significant survival advantage over the individual treatments. Although patients with a relatively low tumour burden may benefit from SCIB2 alone, these results highlight the potential benefits of combining SCIB2 with CTLA-4 blockade, such as ipilimumab, for the treatment of patients with advanced disease. SCIB2 is a DNA plasmid targeting the cancer antigen NY-ESO-1. It induces high avidity CD8 and CD4 responses in pre-clinical models and unlike SCIB1 which is only suitable for patients with the HLA-A2 subtype (around 50% of patients), SCIB2 has been engineered to be effective in over 90% of immune subtypes, further enhancing the market potential and reducing the need for HLA screening prior to treatment. All future ImmunoBody vaccines will now be engineered to this new standard. Checkpoint inhibitors can enable the host immune system to recognise, attack and destroy cancer cells. However, checkpoint inhibitors will not work on their own if the patient fails to mount an adequate immune response to the tumour. Taking the brake off immunosuppressive T cells with either CTLA-4 or PD-1 blockade, whilst simultaneously pressing the accelerator with active immunotherapies such as SCIB1 or SCIB2, is increasingly regarded as offering potential for overwhelming the disease and increasing efficacy.

Scancell Holdings PLC Reports Unaudited Consolidated Earnings Results for the Six Months Ended October 31, 2014

Scancell Holdings PLC reported unaudited consolidated earnings results for the six months ended October 31, 2014. For the period, the company's operating loss was £1,560,813 compared to £1,306,556 a year ago. Loss before taxation was £1,489,915 compared to £1,302,574 a year ago. Loss attributable to equity holders of the parent company was £1,339,915 or £0.60 per basic and diluted share compared to £1,187,574 or £0.57 per basic and diluted share a year ago. Net cash used in operating activities was £1,335,080 compared to £1,170,006 a year ago. The major reason for the increased loss in the period is additional expenditure on development which has been partially offset by a reduction in administration expenses.

Scancell Holdings Plc Announces Change of Registered Office

Scancell Holdings Plc announced the change of the company's registered office to: Eversheds House, 70 Great Bridgewater Street, Manchester, M1 5ES, United Kingdom.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLP:LN 28.75 GBp +0.50

SCLP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SCLP.
View Industry Companies

Industry Analysis


Industry Average

Valuation SCLP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCANCELL HOLDINGS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at